2022年非小细胞肺癌重要临床研究纵览与解读  

An Overview and Interpretation of Important Clinical Studies on Non⁃Small Cell Lung Cancer in 2022

作　　者：刘思阳 甘彬 吴一龙 LIU Si-yang Maggie;GAN Bin;WU Yi-long(Guangdong Lung Cancer Institute,Guangdong Provincial People‘s Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,China;Department of Hematology,The First Affiliated Hospital,Jinan University,Guangzhou 510630,China)

机构地区：[1]广东省肺癌研究所,南方医科大学附属广东省人民医院(广东省医学科学院),广州510080 [2]暨南大学附属第一医院血液科,广州510630

出　　处：《循证医学》2023年第5期311-320,共10页The Journal of Evidence-Based Medicine

基　　金：中国博士后基金项目(2021M701422);广东省肺癌转化医学重点实验室(2017B030314120);广东省医学领军人才配套科研项目(KJ012019426)。

摘　　要：非小细胞肺癌(non-small cell lung cancer,NSCLC)研究在肿瘤学个体化治疗中一直处于领先地位,无论是围术期、局部晚期或晚期NSCLC都陆续有重磅的研究成果报导。值得强调的是,保持创新性对进一步改善肺癌个性化治疗具有非常重要的意义,如何做好临床试验和转化研究、甚至将二者更好的结合是目前亟待思考的问题。本文简要综述了2022年发表的重磅转化研究成果、改变临床实践的临床试验结果以及具有重要影响的肺癌研究进展。Non⁃small cell lung cancer(NSCLC)research has been at the forefront of personalized treatment in oncology,with significant results reported in perioperative,locally advanced,and advanced NSCLC.It is important to note that maintaining innovation is a key factor in the development of lung cancer treatment,and it is worth considering how clinical and translational research can be well combined.Therefore,this article will briefly review important translational research,clinical research that will change the practice of NSCLC treatment,and important impactful research advances in 2022.

关 键 词：非小细胞肺癌 转化研究 个体化治疗 免疫治疗 靶向治疗 新辅助治疗 

分 类 号：R734.2[医药卫生—肿瘤]